Factors influencing the effectiveness of trabeculectomy: following materials of the City Multidisciplinary Hospital No. 2

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Despite the ever-expanding arsenal of IOP-lowering surgeries, trabeculectomy remains the most common procedure amongst them. Therefore, the identification of factors reducing its effectiveness and potentially being able to change the surgical treatment plan is of particular importance.

AIM: To identify factors reducing trabeculectomy effectiveness.

MATERIALS AND METHODS: The study group consisted of 443 consecutively enrolled patients who were operated in 2016–2020 in Saint Petersburg City Multidisciplinary Hospital No. 2 for primary open-angle decompensated glaucoma and then observed for 6 to 24 months. Using statistical research methods, factors that significantly affected the impact of the procedure were identified.

RESULTS: The main predictors of trabeculectomy failure following the order of decreasing importance of established relations (p) were: loss of effectiveness of the preceding IOP-lowering procedure (р = 0.0001), dry eye syndrome (р = 0.013), number of drop instillations per day (р = 0.041), and excessive preservative load due to unnecessarily aggressive topical glaucoma treatment (р = 0.039). An obvious demonstration of excessive therapy is a simultaneous administration of four IOP-lowering medications. It also causes scarring of the procedure area, especially in patients previously operated for glaucoma. Null preservative load and prostaglandin monotherapy are associated with guaranteed “complete success” of trabeculectomy. Unlike the intensity of medical glaucoma treatment, its duration does not have such a significant impact on trabeculectomy outcomes (р = 0.270). Close to a significant one is the relationship between poor surgical outcomes and advanced stages of the disease (р = 0.052).

CONCLUSIONS: The main factors affecting the effectiveness of trabeculectomy were failure of the previous IOP-lowering surgeries; concomitant dry eye syndrome, arising or being aggravated by unduly intense and prolonged pharmacological effects on the eye surface; as well as delayed appliance for surgical IOP normalization at advanced disease stages.

About the authors

Аnastasiia V. Аntonova

City Multidisciplinary Hospital No. 2; Saint Petersburg State University

Author for correspondence.
Email: dr.antonova.av@gmail.com
ORCID iD: 0000-0002-2639-2765
SPIN-code: 2166-3936

Ophthalmologist, Assistant of the Department of ENT Diseases and Ophthalmology

Russian Federation, 5, Uchebnyi lane, Saint Petersburg, 194354; Saint Petersburg

Vadim P. Nikolaenko

City Multidisciplinary Hospital No. 2; Saint Petersburg State University

Email: dr.Nikolaenko@mail.ru
ORCID iD: 0000-0002-6393-1289
SPIN-code: 4906-2542

Dr. Sci. (Med.), Deputy Head Doctor for Ophthalmology, Professor of the Department of ENT Diseases and Ophthalmology

Russian Federation, 5, Uchebnyi lane, Saint Petersburg, 194354; Saint Petersburg

Vladimir V. Brzheskiy

St. Petersburg State Pediatric Medical University

Email: vvbrzh@yandex.ru
ORCID iD: 0000-0001-7361-0270

Dr. Sci. (Med.), Professor, Head of the Department of Ophthalmology

Russian Federation, Saint Petersburg

Aleksandr Ja. Vuks

V.M. Bekhterev St. Petersburg Psychoneurological Research Institute

Email: ayavuks@bekhterev.ru
ORCID iD: 0000-0002-6700-0609

Head Specialist

Russian Federation, Saint Petersburg

References

  1. Egorova EA, Ericheva VP, editors. Natsionalnoe rukovodstvo po glaukome dlya prak-tikuyushchikh vrachei. Moscow: GEHOTAR-Media, 2019. 384 p. (In Russ.) doi: 10.33029/9704-5442-8-GLA-2020-1-384
  2. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5. Savona: PubliComm, 2020. 169 p.
  3. Avo-portal.ru [Internet]. Klinicheskie rekomendatsii. Glaukoma pervichnaya otkrytougol’naya. 2020 [cited: 2022 Nov 25]. Available at: http://avo-portal.ru/doc/fkr/item/246-glaukomaotkrytougolnaya (In Russ.)
  4. Tanna AP. Basic and Clinical Science Course. Section 10. Glaucoma. American Academy of Ophthalmology. San Francisco: AAO, 2022–2023. 319 p.
  5. Weinreb RN, Ramulu P, Topouzis F, et al. editors. 11th Consensus Meeting: Glaucoma Surgery. World Glaucoma Association; 2019 Mar 26; Melbourne, Australia. Available at: https://wga.one/wga/consensus-11/
  6. Brzheskii VV. Glaukoma i sindrom “sukhogo glaza”. Moscow: BORGES, 2018. 228 p. (In Russ.)
  7. Gupta PK, Drinkwater OJ, Van Dusen KW, et al. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg. 2018;44(9):1090–1096. doi: 10.1016/j.jcrs.2018.06.026
  8. Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017;27(6):694–704. doi: 10.5301/ejo.5000977
  9. Antonova AV, Nikolaenko VP, Brzheskiy VV. Realization of a cascade treatment algorithm for glaucoma in St. Petersburg. Russian Journal of Clinical Ophthalmology. 2021;21(3):123–128. (In Russ.) doi: 10.32364/2311-7729-2021-21-3-123-128
  10. Erichev VP, Petrov SYu, Antonov AA, Volzhanin AV. International standards of clinical trials in glaucoma surgery. National Journal glaucoma. 2016;15(2):102–112. (In Russ.)
  11. Shaarawy T, Grehn F, Sherwood M, editors. Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association. Amsterdam: Kugler Publications, 2009. 83 p.
  12. Oblovatskaya ES, Nikolaenko VP. Ahmed valve implant and its place in the surgical treatment of glaucoma. National Journal Glaucoma. 2022;21(2):35–41. (In Russ.) doi: 10.53432/2078-4104-2022-21-2-35-41
  13. Fogagnolo P, Torregrossa G, Tranchina L, et al. Tear film osmolarity, ocular surface disease and glaucoma: a review. Curr Med Chem. 2019;26(22):4241–4252. doi: 10.2174/0929867326666190725160621
  14. Nijm LM, De Benito-Llopis L, Rossi GC, et al. Understanding the dual dilemma of dry eye and glaucoma: an international review. Asia Pac J Ophthalmol (Phila). 2020;9(6):481–490. doi: 10.1097/APO.0000000000000327
  15. Voicu L, Salim S. New strategies for the management of ocular surface disease in glaucoma patients. Curr Opin Ophthalmol. 2021;32(2):134–140. doi: 10.1097/ICU.0000000000000739
  16. Safonova TN, Fedorov AA, Zabegaylo AO, et al. Treatment of dry eye syndrome by primary glaucoma. National Journal Glaucoma. 2015;14(4):36–43. (In Russ.)
  17. Egorova GB, Averich VV. Reducing cytotoxic action of the preservative employed in ophthalmic hypotensive medications with tear replacement therapy. The Russian Annals of Ophthalmology. 2018;134(3):48–56. (In Russ.) doi: 10.17116/oftalma2018134348
  18. Makashova NV, Vasilieva AE, Kolosova OYu. Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops. The Russian Annals of Ophthalmology. 2018;134(2):59–65. (In Russ.) doi: 10.17116/oftalma2018134259-65
  19. Tailor R, Batra R, Mohamed S. A national survey of glaucoma specialists on the preoperative (trabeculectomy) management of the ocular surface. Semin Ophthalmol. 2016;31(6):519–525. doi: 10.3109/08820538.2014.986585
  20. Erichev VP, Volzhanin AV. Non-preservative glaucoma treatment. National Journal glaucoma. 2020;19(1):69–78. (In Russ.) DOI: 10.25700/ NJG.2020.01.10
  21. Baudouin C. Ocular Surface and External Filtration Surgery: Mutual Relationships. Dev Ophthalmol. 2017;59:67–79. doi: 10.1159/000458487
  22. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83:100916. doi: 10.1016/j.preteyeres.2020.100916
  23. Astakhov YuS, Nikolaenko VP, editors. Oftalmologiya. Farmakoterapiya bez oshibok II. Moscow: E-noto, 2021. 800 p. (In Russ.)
  24. Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J Glaucoma. 2013;22(9): 730–735. doi: 10.1097/IJG.0b013e31825af67d
  25. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1154. doi: 10.1001/archopht.1994.01090230060021
  26. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437–1145. doi: 10.1001/archopht.1994.01090230051020
  27. Richter CU, Shingleton BJ, Bellows AR, et al. The development of encapsulated filtering blebs. Ophthalmology. 1988;95(9):1163–1168. doi: 10.1016/s016-6420(88)33041-1
  28. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543–1548. doi: 10.1001/archopht.1990.01070130045027

Copyright (c) 2023 ECO-vector LLC


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies